OVERVIEW OF ACTIVITY

Given the prevalent nature of the disease, extensive resources are allocated to colorectal cancer (CRC) research and education. Interestingly, however, although individually less frequently encountered, the collection of other, “non-CRC” gastrointestinal (GI) neoplasms accounts for more per annum cancer-related deaths than those attributed to tumors of the colon and rectum combined. Educational opportunities relevant to the clinical management of both CRC and non-CRC GI tumors are essential to general oncologist delivery of comprehensive cancer care. The introduction of novel biomarkers, genomic signatures and molecular-targeted systemic agents has led to a rapid paradigm shift in the clinical algorithms for these diseases that presents a challenge to practicing oncologists who must grapple with the presentation of ambiguous data sets and their immediate impact on treatment decisions. To bridge the gap between research and patient care, this CME activity uses the input of cancer experts and community physicians to frame a relevant discussion of recent research advances in GI cancers that can be applied to routine clinical practice. This information will help medical oncologists and hematology-oncology fellows formulate up-to-date clinical management strategies for patients.

LEARNING OBJECTIVES

• Apply the results of emerging clinical research to the best-practice management of select GI cancers originating within (CRC) and outside of (non-CRC) the colon and rectum.
• Employ biomarkers and novel genomic signatures in counseling patients with Stage II colon cancer about the long-term risk of disease recurrence.
• Communicate the benefits and risks of anti-VEGF and anti-EGFR biologic therapy to patients with metastatic CRC.
• Evaluate the role of potential radiosensitizers in the multimodality management of locally advanced rectal cancer.
• Use clinical and molecular biomarkers to select optimal local and systemic treatment strategies for patients with gastric or gastroesophageal cancer.
• Effectively integrate the evidence-based use of chemotherapy and molecular-targeted agents into the individualized management of advanced pancreatic cancer.
• Communicate the benefits and risks of existing and emerging systemic and targeted treatments for patients with advanced hepatocellular or biliary tract cancer.